Posts by: Iqra Mumal

News

The presence of specific subtypes of immune cells in the tumor environment of people with follicular lymphoma can predict how a patient’s immune system will respond to the disease, ... Read more

October 5, 2018

MEDI0457 with Anti-PD-1 Therapy Shows Promise in Treating HPV-associated Head and Neck Cancer

News

An investigational cancer vaccine, MedImmune’s MEDI0457, can safely be used in combination with anti-PD-1 therapy to improve outcomes in patients with HPV-associated head and neck cancer, a study reports, ... Read more

September 7, 2018September 7, 2018

Affimed and Genentech Partner to Develop Immunotherapies Against Cancer Based on Natural Killer Cells

News

A recent collaboration between Affimed and Genentech, a member of the Roche group, aims to develop immunotherapies — called engager-based immunotherapies — that aim to establish a bridge between a patient’s own immune cells and ... Read more

August 24, 2018August 24, 2018

High Nitrogen Levels Can Increase Cancer Cell Growth, But Also Enhance Immunotherapy Response, Study Suggests

News

While dysregulation of the urea cycle gives a growth advantage to cancer cells, it also makes them more amenable to immunotherapy, a study reports. The study, “Urea Cycle Dysregulation ... Read more

August 15, 2018

New Method Uses Bioinformatics to Monitor Immunotherapy Response to Cancer

News

A newly developed method that combines sequencing with bioinformatics can help monitor the effectiveness of immunotherapy in patients being treated for cancer, according to Johns Hopkins researchers. Their study, “The ... Read more

May 2, 2018May 2, 2018

EMA to Review Keytruda Combo as First-line Treatment for Advanced NSCLC Patients in EU

News

The European Medicines Agency (EMA) has started the review process for Merck‘s application seeking approval of Keytruda (pembrolizumab) in combination with Alimta (pemetrexed) and platinum chemotherapy as a first-line treatment for ... Read more

March 26, 2018March 26, 2018

Venclexta-Rituxan Combo Delays Disease Progression in Lymphocytic Leukemia, Trial Results Show

News

Treatment of patients with relapsed or refractory chronic lymphocytic leukemia with a combination of Venclexta (venetoclax) plus Rituxan (rituximab) significantly extended the time a patient lived without signs of disease ... Read more

February 9, 2018February 14, 2018

PD-1 Inhibitors May Help Children with Certain Form of Aggressive Brain Cancer, Study Says

News

Immune checkpoint inhibitors targeting the PD-1 pathway could be a promising approach in treating certain children with an aggressive form of brain cancer known as supratentorial pediatric ependymoma, researchers suggest. ... Read more

November 22, 2017November 22, 2017

Seattle Children’s Launches 2-Pronged CAR T-Cell Therapy Trial in Refractory Acute Lymphoblastic Leukemia

News

Seattle Children’s Hospital has launched a new clinical trial, PLAT-05 (NCT03330691), and is currently recruiting participants to test a new CAR T-cell immunotherapy targeting two proteins expressed on cancer cells of ... Read more

November 7, 2017November 7, 2017

Super T-cells that Launch Dual Attack on Cancer Cells Enter Clinical Evaluation

News

Researchers at Roswell Park Cancer Institute in upstate New York have started a Phase 1/2a clinical trial to evaluate the use of “super T-cells” for the treatment of solid-tumor cancers. The ... Read more

Posts by: Iqra Mumal

Iqra Mumal

Subtypes of Immune Cells in Tumor Environment Can Predict Follicular Lymphoma Response to Therapy

MEDI0457 with Anti-PD-1 Therapy Shows Promise in Treating HPV-associated Head and Neck Cancer

Affimed and Genentech Partner to Develop Immunotherapies Against Cancer Based on Natural Killer Cells

High Nitrogen Levels Can Increase Cancer Cell Growth, But Also Enhance Immunotherapy Response, Study Suggests

New Method Uses Bioinformatics to Monitor Immunotherapy Response to Cancer

EMA to Review Keytruda Combo as First-line Treatment for Advanced NSCLC Patients in EU

Venclexta-Rituxan Combo Delays Disease Progression in Lymphocytic Leukemia, Trial Results Show

PD-1 Inhibitors May Help Children with Certain Form of Aggressive Brain Cancer, Study Says

Seattle Children’s Launches 2-Pronged CAR T-Cell Therapy Trial in Refractory Acute Lymphoblastic Leukemia

Super T-cells that Launch Dual Attack on Cancer Cells Enter Clinical Evaluation

Pin It on Pinterest